Division of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
Eur J Cancer. 2010 Jul;46(11):1967-78. doi: 10.1016/j.ejca.2010.04.004. Epub 2010 May 5.
Nasopharyngeal carcinoma (NPC) differs from other head and neck cancers in its aetiology, epidemiology and potential therapeutic options. Despite cure for the majority of the patients, challenges still exist in the prevention of disease relapse, treatment of patients with refractory or metastatic NPC and the management of long-term toxicities. This article discusses the specific challenges in pushing the boundaries of NPC treatments further, with an emphasis on prognostic/predictive markers, molecularly targeted therapies, immunotherapies and the areas of interest with regard to long-term toxicities arising from therapeutic interventions.
鼻咽癌（NPC）在病因学、流行病学和潜在治疗选择方面与其他头颈部癌症不同。尽管大多数患者可以治愈，但在预防疾病复发、治疗难治性或转移性 NPC 患者以及管理治疗相关长期毒性方面仍然存在挑战。本文讨论了进一步推动 NPC 治疗进展的具体挑战，重点介绍了预后/预测标志物、分子靶向治疗、免疫治疗以及治疗干预相关长期毒性的关注领域。
